Search results for: Determining Value
Filter search results
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…precision treatment. He points out the importance, with respect to the latter, of the importance of appropriately valuing the diagnostics that are essential to realising the full value of treatment. To…
What Is the Role of Cost-Effectiveness Evidence in US Health Care?
31 July 2013
…value of expanding that. At an OHE seminar last week, Dr James Chambers of Tufts Medical School examined the role cost-effectiveness evidence plays in health care resource allocation in the…
ISPOR Task Force Report on Performance-Based Risk-Sharing Arrangements
28 August 2013
…Washington and Visiting Senior Research Fellow at the OHE, and Professor Adrian Towse, Director of the OHE. The report appeared in late August in Value in Health. The idea of…
NICE Decisions: Cost-effectiveness is the Most Significant Predictor
21 November 2013
…(NICE) undertakes appraisals of selected technologies and issues guidance intended to ensure quality and value for money. Its decisions are binding within the NHS and also affect decisions by health…
Mikel Berdud
26 February 2015
Mikel Berdud is an economist specialised in pharmaceutical R&D incentives, pricing and reimbursement, and social value of innovation. He holds a PhD in the topic of economics of organizations and…
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
…Danzon of the Wharton School at the University of Pennsylvania to examine value-based pricing for pharmaceuticals. The research explores which approaches to pricing can produce the greatest efficiency within and…
Use of Cost-effectiveness Evidence in US Health Care: Seminar Briefing
1 April 2014
Just published by OHE, this Seminar Briefing summarises remarks at an OHE Lunchtime Seminar by Dr James Chambers of the Center for the Evaluation of Value and Risk in Health…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
…NICE assesses the value of a health technology is scheduled to be completed in June 2014. In a presentation at the PharmaAccess Leader’s Forum, Martin Garau summarised the proposed changes…
OHE Lunchtime Seminar: Health Years in Total (HYT): A New Health Objective Function for Cost-effectiveness Analysis
20 June 2019
…public decision making on health care (e.g. Medicare). Alternatives to the QALY (such as Equal Value of Life, EVL) have not gained traction as their use raises other efficiency issues….